GSK and Gilead Sciences to execute a strategic license agreement for antiviral agentr

Published: 2002-05-15 06:57:00

Updated: 2002-05-15 06:57:00

GlaxoSmithKline says that it signed with Gilead Sciences a strategic license agreement for the commercialization of antiviral agent (adefovir dipivoxil). Adefovir dipivoxil tablet (10mg once daily) for the treatment of chronic hepatitis B virus is now in phase III clinical trials and its application for market authorization is now underway in U.S. and Europe countries. Under the agreement:

...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.